NCT07095686Enrolling By Invitation1 期
An Open-Label Study of an Experimental Antisense Oligonucleotide Treatment for Amyotrophic Lateral Sclerosis (ALS) Due to an Arg15Leu Pathogenic Variant in CHCHD10
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- Enrolling By Invitation
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Clinical Functioning
研究概览
简要总结
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for individual participants with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representatives(s)
- •Ability to travel to the study site and adhere to study related follow-up examinations and/or procedures and provide access to participant's medical records
- •Genetically confirmed neurological disorder
排除标准
- •Participant has any condition that in the opinion of the Site Investigator would ultimately prevent the completion of study procedures
- •Use of an investigational medication within less than 5 half-lives of the drug at enrollment
研究组 & 干预措施
Open Label nL-CHCHD-001
Experimental
干预措施: nL-CHCHD-001 (Drug)
结局指标
主要结局
Clinical Functioning
时间窗: Baseline to 12 months
Change from baseline at 12-months post nL-CHCHD-001 administration in scores on Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R).
Motor Function
时间窗: Baseline to 12 months
Change from baseline at 12-months post nL-CHCHD-001 administration in Slow Vital Capacity (SVC)
次要结局
- Disease Biomarkers(Baseline to 12 months)
- Safety and Tolerability(Baseline to 12 months)
- Safety and tolerability(Baseline to 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALSAmyotrophic Lateral SclerosisNCT06392126n-Lorem Foundation1
进行中（未招募）
1 期
Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALSNCT06977451n-Lorem Foundation1
进行中（未招募）
1 期
Personalized Antisense Oligonucleotide Therapy for a Single Participant with ATN1 Gene MutationDentatorubral-Pallidoluysian AtrophyNCT06706388n-Lorem Foundation1
Enrolling By Invitation
1 期
Single Participant Study of an Experimental ASO Treatment for TUBB4A-related LeukodystrophyGenetic DiseaseNCT06369974Massachusetts General Hospital1
进行中（未招募）
1 期
Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2AGenetic DiseaseNCT06314490University of California, San Diego1